{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T10:14:36Z","timestamp":1794478476124,"version":"4.9.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2026NSFSC1777"],"award-info":[{"award-number":["2026NSFSC1777"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["GZB20250525"],"award-info":[{"award-number":["GZB20250525"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Gastrointestinal Surgery"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.gassur.2026.102411","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T01:59:20Z","timestamp":1775181560000},"page":"102411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The role of circulating tumor DNA in precision adjuvant therapy for colorectal cancer: a scoping review"],"prefix":"10.1016","volume":"30","author":[{"given":"Tianxiang","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjian","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haining","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2874-1535","authenticated-orcid":false,"given":"Ziqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.gassur.2026.102411_bib1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"10.1016\/j.gassur.2026.102411_bib2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","article-title":"Integrating liquid biopsies into the management of cancer","volume":"14","author":"Siravegna","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"346","key":"10.1016\/j.gassur.2026.102411_bib3","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf6219","article-title":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","volume":"8","author":"Tie","year":"2016","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.gassur.2026.102411_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/s41576-018-0071-5","article-title":"Current and future perspectives of liquid biopsies in genomics-driven oncology","volume":"20","author":"Heitzer","year":"2019","journal-title":"Nat Rev Genet"},{"issue":"4","key":"10.1016\/j.gassur.2026.102411_bib5","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/2159-8290.CD-20-1311","article-title":"Liquid biopsy: from discovery to clinical application","volume":"11","author":"Alix-Panabi\u00e8res","year":"2021","journal-title":"Cancer Discov"},{"issue":"17","key":"10.1016\/j.gassur.2026.102411_bib6","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1016\/j.scib.2025.06.030","article-title":"Liquid biopsy-based multi-cancer early detection: an exploration road from evidence to implementation","volume":"70","author":"Xu","year":"2025","journal-title":"Sci Bull"},{"issue":"8","key":"10.1016\/j.gassur.2026.102411_bib7","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","article-title":"Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer","volume":"5","author":"Reinert","year":"2019","journal-title":"JAMA Oncol"},{"issue":"24","key":"10.1016\/j.gassur.2026.102411_bib8","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.gassur.2026.102411_bib9","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1158\/1078-0432.CCR-18-3663","article-title":"Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence","volume":"25","author":"Coombes","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.gassur.2026.102411_bib10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","article-title":"Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer","volume":"29","author":"Kotani","year":"2023","journal-title":"Nat Med"},{"issue":"16","key":"10.1016\/j.gassur.2026.102411_bib11","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2025.43.16_suppl.3503","article-title":"ctDNA-guided adjuvant chemotherapy escalation in stage III colon cancer: primary analysis of the ctDNA-positive cohort from the randomized AGITG dynamic-III trial (intergroup study of AGITG and CCTG)","volume":"43","author":"Tie","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.gassur.2026.102411_bib12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/JCO.2024.42.3_suppl.5","article-title":"Phase II results of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA) phase II\/III study","volume":"42","author":"Morris","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.gassur.2026.102411_bib13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.2025.43.4_suppl.15","article-title":"Circulating tumor DNA for detection of molecular residual disease (MRD) in patients (pts) with stage II\/III colorectal cancer (CRC): final analysis of the BESPOKE CRC sub-cohort","volume":"43","author":"Shah","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.gassur.2026.102411_bib14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1158\/1078-0432.CCR-20-2299","article-title":"Serial circulating tumor DNA in predicting and monitoring the effect of neoadjuvant chemoradiotherapy in patients with rectal cancer: a prospective multicenter study","volume":"27","author":"Zhou","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.gassur.2026.102411_bib15","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.gassur.2026.102411_bib16","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.gassur.2026.102411_bib17","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jamaoncol.2020.2295","article-title":"Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer: preplanned secondary analysis of the BRE12-158 randomized clinical trial","volume":"6","author":"Radovich","year":"2020","journal-title":"JAMA Oncol"},{"issue":"23","key":"10.1016\/j.gassur.2026.102411_bib18","doi-asserted-by":"crossref","first-page":"9530","DOI":"10.1073\/pnas.1105422108","article-title":"Detection and quantification of rare mutations with massively parallel sequencing","volume":"108","author":"Kinde","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"10.1016\/j.gassur.2026.102411_bib19","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1001\/jamaoncol.2019.3616","article-title":"Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for Stage III colon cancer","volume":"5","author":"Tie","year":"2019","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.gassur.2026.102411_bib20","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1158\/1078-0432.CCR-21-2404","article-title":"Circulating tumor DNA in Stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences","volume":"28","author":"Henriksen","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.gassur.2026.102411_bib21","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.3390\/ijms26073403","article-title":"Prospective upfront next-generation sequencing for advanced non-small cell lung cancer: real-world outcomes from the Ion Chiricu\u021b\u0103 oncology institute","volume":"26","author":"Preda","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"20","key":"10.1016\/j.gassur.2026.102411_bib22","doi-asserted-by":"crossref","first-page":"5586","DOI":"10.1158\/1078-0432.CCR-21-0410","article-title":"Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer","volume":"27","author":"Parikh","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"7655","key":"10.1016\/j.gassur.2026.102411_bib23","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.gassur.2026.102411_bib24","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1158\/1078-0432.CCR-24-0226","article-title":"Tissue-free liquid biopsies combining genomic and methylation signals for minimal residual disease detection in patients with early colorectal cancer from the UK TRACC Part B Study","volume":"30","author":"Slater","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.gassur.2026.102411_bib25","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/cam4.5008","article-title":"Detection of methylated BCAT1 and IKZF1 after curative-intent treatment as a prognostic indicator for colorectal cancer recurrence","volume":"12","author":"Pedersen","year":"2023","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.gassur.2026.102411_bib26","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/s41591-025-03579-w","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial","volume":"31","author":"Tie","year":"2025","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.gassur.2026.102411_bib27","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1136\/gutjnl-2017-315852","article-title":"Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study","volume":"68","author":"Tie","year":"2019","journal-title":"Gut"},{"issue":"17","key":"10.1016\/j.gassur.2026.102411_bib28","article-title":"Longitudinal circulating tumor DNA monitoring in predicting response to short-course neoadjuvant radiotherapy in locally advanced rectal cancer: data from a phase III clinical trial (UNION)","volume":"42","author":"Lin","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.gassur.2026.102411_bib29","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12885-023-10699-4","article-title":"ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C)","volume":"23","author":"Slater","year":"2023","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.gassur.2026.102411_bib30","first-page":"604","article-title":"Minimal residual disease-directed adjuvant therapy for patients with early-stage colon cancer: CIRCULATE-US","volume":"36","author":"Sahin","year":"2022","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.gassur.2026.102411_bib31","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1080\/0284186X.2019.1711170","article-title":"IMPROVE-IT2: implementing noninvasive circulating tumor DNA analysis to optimize the operative and postoperative treatment for patients with colorectal cancer - intervention trial 2. Study protocol","volume":"59","author":"Nors","year":"2020","journal-title":"Acta Oncol"},{"issue":"1","key":"10.1016\/j.gassur.2026.102411_bib32","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1186\/s12885-020-07252-y","article-title":"Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study","volume":"20","author":"Schraa","year":"2020","journal-title":"BMC Cancer"},{"issue":"16","key":"10.1016\/j.gassur.2026.102411_bib33","article-title":"NSAB C-14: CORRECT-MRD II\u2014second colorectal cancer clinical validation study to predict recurrence using a circulating tumor DNA assay to detect minimal residual disease","volume":"40","author":"Salem","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.gassur.2026.102411_bib34","doi-asserted-by":"crossref","first-page":"S169","DOI":"10.1200\/JCO.2023.41.4_suppl.169","volume":"41","author":"Slater","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.gassur.2026.102411_bib35","article-title":"Circulating tumor DNA guided therapeutic strategies for colorectal cancer patients with multiple small pulmonary-limited nodules: an open-label, prospective, phase II cohort study","volume":"41","author":"Chang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.gassur.2026.102411_bib36","article-title":"A randomized, double-blind, phase III study comparing trifluridine\/tipiracil (FTD\/TPI) versus placebo in patients with molecular residual disease following curative resection of colorectal cancer (CRC): the ALTAIR study","volume":"43","author":"Bando","year":"2025","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.gassur.2026.102411_bib37","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1111\/cas.14926","article-title":"CIRCULATE-Japan: circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer","volume":"112","author":"Taniguchi","year":"2021","journal-title":"Cancer Sci"},{"issue":"Suppl 3","key":"10.1016\/j.gassur.2026.102411_bib38","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1200\/JCO.2024.42.3_suppl.148","article-title":"Early identification and treatment of occult metastatic disease in stage III colon cancer (SU2C ACT3 clinical trial)","volume":"42","author":"Pappas","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gassur.2026.102411_bib39","doi-asserted-by":"crossref","unstructured":"Peng J, Ding C, Mo S, Zhou C, Ma M, Lu P, et al. Dynamic ctDNA methylation\u2011guided postoperative surveillance in non-metastatic colorectal cancer: interim analysis of the phase III FIND trial. In: Proceedings of the ESMO gastrointestinal cancers congress; 2025: Abstract LBA1.","DOI":"10.1016\/j.annonc.2025.05.541"},{"issue":"11","key":"10.1016\/j.gassur.2026.102411_bib40","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1038\/s41591-024-03254-6","article-title":"ctDNA-based molecular residual disease and survival in resectable colorectal cancer","volume":"30","author":"Nakamura","year":"2024","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.gassur.2026.102411_bib41","article-title":"Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: findings from CALGB (Alliance)\/SWOG 80702","volume":"43","author":"Nowak","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.gassur.2026.102411_bib42","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1200\/JCO.2024.42.3_suppl.9","article-title":"Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II\/III colorectal cancer (CRC): interim analysis of BESPOKE CRC study","volume":"42","author":"Kasi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.gassur.2026.102411_bib43","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1200\/OP.24.00167","article-title":"Clinical applications of circulating tumor DNA profiling in GI cancers","volume":"20","author":"Battaglin","year":"2024","journal-title":"JCO Oncol Pract"},{"issue":"24","key":"10.1016\/j.gassur.2026.102411_bib44","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1200\/JCO.21.02615","article-title":"Using circulating tumor DNA in colorectal cancer: current and evolving practices","volume":"40","author":"Malla","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.gassur.2026.102411_bib45","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1200\/JCO.2024.42.3_suppl.54","article-title":"Patient-reported outcomes from the BESPOKE CRC study","volume":"42","author":"Kasi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2 D","key":"10.1016\/j.gassur.2026.102411_bib46","article-title":"Colon cancer, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Benson","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"issue":"1","key":"10.1016\/j.gassur.2026.102411_bib47","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.gassur.2026.102411_bib48","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41698-025-00876-y","article-title":"Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology","volume":"9","author":"Bartolomucci","year":"2025","journal-title":"NPJ Precis Oncol"},{"issue":"2","key":"10.1016\/j.gassur.2026.102411_bib49","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s43018-019-0011-0","article-title":"Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small cell lung cancer","volume":"1","author":"Moding","year":"2020","journal-title":"Nat Cancer"}],"container-title":["Journal of Gastrointestinal Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091255X26000922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091255X26000922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:38:09Z","timestamp":1778798289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1091255X26000922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1091255X26000922"],"URL":"https:\/\/doi.org\/10.1016\/j.gassur.2026.102411","relation":{},"ISSN":["1091-255X"],"issn-type":[{"value":"1091-255X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of circulating tumor DNA in precision adjuvant therapy for colorectal cancer: a scoping review","name":"articletitle","label":"Article Title"},{"value":"Journal of Gastrointestinal Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gassur.2026.102411","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Society for Surgery of the Alimentary Tract. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102411"}}